Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 14.1% in December

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 16,400 shares, a drop of 14.1% from the December 15th total of 19,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 25,600 shares, the short-interest ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research report on Wednesday, December 11th.

Institutional Investors Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Stock Performance

Shares of Lisata Therapeutics stock traded down $0.01 during trading on Friday, reaching $3.71. The company’s stock had a trading volume of 71,879 shares, compared to its average volume of 42,044. Lisata Therapeutics has a one year low of $2.19 and a one year high of $4.20. The firm has a market cap of $31.13 million, a price-to-earnings ratio of -1.48 and a beta of 1.14. The business’s fifty day moving average price is $3.03 and its 200-day moving average price is $3.06.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.16. During the same period last year, the business earned ($0.65) EPS. Sell-side analysts anticipate that Lisata Therapeutics will post -2.66 EPS for the current year.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.